Effects of Energy Drinks on Sleep and Cardiovascular Health
NCT ID: NCT05503732
Last Updated: 2024-11-15
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
54 participants
INTERVENTIONAL
2022-09-01
2024-09-06
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Cardiovascular Effects of Energy Drinks in Healthy Adults
NCT01940822
Energy Drink Effects on Performance, Mood, and Cardiovascular Outcomes
NCT05559372
The Effect of Energy Drink Ingredients on Cardiovascular Function in Men and Women 18-39 Years Old
NCT04149717
Impact of Energy Drinks on Cardiovascular Endpoints
NCT01329679
Energy Drinks and Vascular Function
NCT03324256
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
PREVENTION
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Energy drink first, then placebo drink
Subjects will consume two 16-oz energy drinks before sleep for the first study visit, then consume two 16-oz identical looking placebo drink before sleep at the second study visit.
Energy Drink
Two 16-oz energy drinks consumed orally to be finished approximately 4 hours prior to bed
Placebo Drink
Two 16-oz identical looking placebo drink without caffeine consumed orally to be finished approximately 4 hours prior to bed
Placebo drink first, than energy drink
Subjects will consume two 16-oz identical looking placebo drink before sleep at the fist study visit, then consume two 16-oz energy drinks before sleep for the second study visit.
Energy Drink
Two 16-oz energy drinks consumed orally to be finished approximately 4 hours prior to bed
Placebo Drink
Two 16-oz identical looking placebo drink without caffeine consumed orally to be finished approximately 4 hours prior to bed
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Energy Drink
Two 16-oz energy drinks consumed orally to be finished approximately 4 hours prior to bed
Placebo Drink
Two 16-oz identical looking placebo drink without caffeine consumed orally to be finished approximately 4 hours prior to bed
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Healthy subjects without known cardiovascular disease and thyroid disease.
* Subjects who are on no medications (except oral contraceptive pill).
* Nonsmokers.
* No prior history of caffeine sensitivity or allergy.
Exclusion Criteria
* Subjects currently taking medications other than oral contraceptive pill.
* Smokers.
* Prior history of caffeine sensitivity or allergy.
* Pregnancy.
* Subjects who regularly consume energy drinks.
* Subjects who typically go to sleep after midnight.
* Subjects who traveled across 2 time zones in the last 7 days.
* Shift workers.
* Subjects who have or are suspected to have sleep apnea.
* Subjects who have a body mass index \> 35kg/m\^2.
18 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Mayo Clinic
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Anna Svatikova
Principal Investigator
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Anna Svatikova, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
Mayo Clinic
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Mayo Clinic Rochester
Rochester, Minnesota, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
21-012902
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.